Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Affirm Holdings Inc (AFRM) vs Moderna, Inc. (MRNA) Price & Performance

Affirm Holdings IncTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Affirm Holdings Inc vs Moderna, Inc. — how do they compare? Affirm Holdings Inc trades at $76.96 (market cap $25.30B), while Moderna, Inc. trades at $60.53 (market cap $23.88B). The key difference: Affirm Holdings Inc and Moderna, Inc. are close in size by market cap. Which is the better fit depends on your goals.

AFRMMRNA
Market Cap
$25.30B$23.88B
Sector
FinancialsHealth
52-Week High
$92.18$81.80
52-Week Low
$42.53$22.36
Enterprise Value
$31.91B$20.03B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Affirm Holdings Inc

AFRM trades at $75.25, down 1.74% on the day, with a bullish technical signal supported by moving averages. The company reported strong revenue growth to $3.22B in 2025, turning profitable with net income of $52.19M, and has beaten EPS estimates in recent quarters. Positive sentiment is driven by analyst optimism and expanding merchant partnerships.

Outlook remains favorable with a consensus price target of $96.00, indicating 28% upside. Risks include high valuation multiples (P/E 68.41) and sensitivity to interest rate changes. Continued execution on growth and profitability will be key for stock performance.

Moderna, Inc.

Moderna (MRNA) stock trades at $59.17, up 9.86% recently, with a bullish technical signal and strong institutional buying interest. The company's Q2 2026 earnings beat expectations, and the FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50+ marks a key post-pandemic milestone. However, fundamentals show declining revenue from $18.9B in 2022 to $1.9B in 2025 and persistent net losses, with a negative net income margin of -142.58% in 2025.

The outlook hinges on pipeline execution; while new vaccine approvals and cost-cutting efforts offer growth potential, the stock faces risks from high valuation multiples and ongoing profitability challenges. Analyst consensus is cautious with a $54.33 price target below the current price, reflecting mixed sentiment amid transitional phase uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Affirm Holdings Inc

Affirm Holdings Inc offers a platform for digital and mobile first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a major share of its revenue from the United States.

Read more on AFRM

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA